









Markets
/
Stocks
/
nasdaq-anix
/

Anixa Biosciences Inc

ANIX

3.300USD

-0.070-2.08%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

108.31MMarket Cap

LossP/E TTM



Anixa Biosciences Inc

3.300

-0.070-2.08%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

180 / 506

Overall Ranking

294 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

9.000

Target Price

+167.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the α-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

Fairly Valued

The company’s latest PE is -8.75, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.25M shares, decreasing 9.62% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.39M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.37.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 4.67, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.67

Change



Financials

1.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.53

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.73

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.93, which is -9.73% below the recent high of -8.06 and -13.10% above the recent low of -10.10.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 180/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Anixa Biosciences Inc is 9.50, with a high of 10.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

9.000

Target Price

+167.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Anixa Biosciences Inc

ANIX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.98, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.67 and the support level at 3.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.98

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.094

Buy

RSI(14)

56.848

Neutral

STOCH(KDJ)(9,3,3)

61.440

Neutral

ATR(14)

0.181

Low Volatility

CCI(14)

68.046

Neutral

Williams %R

44.776

Buy

TRIX(12,20)

0.318

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.428

Sell

MA10

3.201

Buy

MA20

3.101

Buy

MA50

3.127

Buy

MA100

3.050

Buy

MA200

2.933

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 22.51%, representing a quarter-over-quarter decrease of 1.87%. The largest institutional shareholder is The Vanguard, holding a total of 1.39M shares, representing 4.23% of shares outstanding, with 2.24% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.39M

Titterton (Lewis H Jr)

933.33K

-3.01%

Laird Norton Wealth Management

622.24K

D.A. Davidson & Co.(Research)

614.27K

-8.46%

Kumar (Amit)

569.92K

+1.79%

UBS Financial Services, Inc.

524.16K

-1.87%

Mission Wealth Management, LP

469.52K

Geode Capital Management, L.L.C.

340.26K

+3.31%

BofA Global Research (US)

210.27K

+0.01%

BlackRock Institutional Trust Company, N.A.

155.13K

-1.59%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.58, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.